The primary focus of the acquisition is on the lead medicine, Tazverik® (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor.

Returning investor OMERS Growth Equity led the round, which also included Fidelity Management & Research Company and other current investors.

Under the definitive agreement, Kineta will become a wholly-owned subsidiary of Yumanity in an all-stock transaction.

Orrick advised South San Francisco-based biopharmaceutical company Catalyst Biosciences, Inc.

Orrick advised Stripes on its investment in digital therapeutics company Hello Heart’s $70 million Series D funding round. 

Orrick advises Twist Bioscience on upsized public offering of common stock.

We advised Dompé farmaceutici S.P.A (Dompé) on its multi-year, multi-program strategic research and development collaboration with Engitix Ltd.

The agreement grants Simcere an exclusive regional license to develop and commercialize AVLX-144, Avilex’s Phase 2-ready dimeric PSD-95 inhibitor.

Opentrons will use this fundraising round to further invest in its automated lab platform globally.

The U.S. Court of Appeals for the Federal Circuit today overturned a $1.2+ billion patent infringement judgment against Gilead’s Kite Pharma unit.

Attilio Mazzilli led a team that assisted Cerba HealthCare, a leader in outpatient diagnostics, in the acquisition of the entire stake of Lifebrain.

Orrick is advising HCW Biologics on its $56 million initial public offering of 7 million shares of common stock. 

Orrick is advising Rafael Pharmaceuticals, a clinical-stage oncology company, on its proposed merger with Rafael Holdings.

Here are five tips for building a robust patent portfolio that provides a solid intellectual property framework.

A Conversation on Leveraging Spinouts to Preserve and Create Value During Financing Rounds, M&A and IPO Planning

The U.S. DOJ Civil Division’s Consumer Protection Branch (CPB) first-ever “Recent Highlights” report leads with CPB’s work on consumer health and ...

A Conversation on the Future of Longevity, Cell Regeneration and Senescence

Six noteworthy trends that life sciences and healthcare companies should continue to keep an eye on in 2022.

Orrick's State Attorneys General team examines recent actions around the United States.

VC Investment Surges in European Life Science

We analyze new rules prohibiting information blocking rules for health tech companies and outline steps they can take to ensure compliance.

The U.S. Federal Trade Commission issued a policy statement providing clarity on the scope of its 2009 Health Breach Notification Rule.

Attacks on the life sciences and healthcare sectors increased significantly in the last year.

A Conversation on Spinouts – Unlocking Market Value and Creating Business Opportunities

Record-breaking Markets and a Candid Conversation on University Spinouts

We review full-year 2020 data in depth to identify and summarize the key trends that shaped venture investment across the sector.

We dig deeper into key underwriting topics for fintech, edtech and healthtech/medtech deals.

This article provides an overview about the recent investment trends in Germany in view of the COVID-19 pandemic.

Congratulations to Orrick partner Gregg Griner on being recognized as a Go-To Lawyer for Healthcare and Life Sciences by Massachusetts Lawyers Weekly.

Welcome to Tony Chan who joins the firm as a partner focused on advising companies and investors in the life sciences and tech sectors.

Eileen Cole and Craig Falls join the firm as partners in our Antitrust and Competition practice.

Orrick welcomes Franklin Monsour, a former federal prosecutor and experienced white collar and regulatory adviser to the life sciences sector.

LMG recognizes the individuals and companies behind the most innovative and challenging life sciences work of the past year.

Orrick announced today that Thora Johnson has joined our Cyber, Privacy & Data Innovation practice as a partner in Washington, DC.